CD19 and polycystic ovary syndrome: Our previous findings also revealed that CD19+ B cell-depleted mice were resistant to DHEA-induced PCOS, while aCD19 Ab treatment markedly ameliorated pathological phenotypes in PCOS mice by inhibiting local and systemic inflammation (25, 34).